Stryker Corporation Announces Pricing of $1.0 Billion Senior Notes Offering

Wed Mar 20, 2013 4:22pm EDT

* Reuters is not responsible for the content in this press release.

For best results when printing this announcement, please click on the link below:

http://pdf.reuters.com/htmlnews/8knews.asp?i=43059c3bf0e37541&u=urn:newsml:reuters.com:20130320:nHUGcZRr


Stryker Corporation (NYSE:SYK) announced today that it has priced an offering to sell $600 million
of senior unsecured notes due 2018 (the "2018 Notes") and $400 million of senior unsecured notes
due 2043 (the "2043 Notes").  The 2018 Notes will bear interest at 1.300% per year and, unless
previously redeemed, will mature on April 1, 2018.  The 2043 Notes will bear interest at 4.100%
per year and, unless previously redeemed, will mature on April 1, 2043.
   
The Company intends to use the net proceeds from the offering for working capital and other
general corporate purposes, including acquisitions, stock repurchases and other business
opportunities. 

Barclays, BofA Merrill Lynch, and Goldman Sachs are acting as active joint book-running managers
for the offering.  This offering was made pursuant to a prospectus supplement to the Company's
prospectus, dated February 28, 2013, filed as part of the Company's effective shelf registration
statement.  Copies of the preliminary prospectus supplement and accompanying prospectus relating
to the notes may be obtained by contacting the joint book-running managers: Barclays Capital Inc.,
Attention: Prospectus Department, 745 Seventh Avenue, New York, New York 102825, or by calling
888-603-5847, or by emailing barclaysprospectus@broadridge.com; Goldman, Sachs & Co., Attention: 
Prospectus Department, 200 West Street, New York, New York 10282, or by calling 866-471-2526, or
by emailing prospectus-ny@ny.email.gs.com; and Merrill Lynch, Pierce, Fenner & Smith Incorporated,
Attention: Prospectus Department, 222 Broadway, 11th Floor, New York, New York 10038, or by
calling 800-294-1322, or by emailing Dg.prospectus_requests@baml.com.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy
any securities nor will there be any sale of these securities in any state or other jurisdiction
in which such offer, solicitation or sale would be unlawful prior to registration or qualification
under the securities laws of any such state or other jurisdiction.

This press release contains information that includes or is based on forward-looking statements
within the meaning of the federal securities law that are subject to various risks and
uncertainties that could cause our actual results to differ materially from those expressed or
implied in such statements. Such factors include, but are not limited to: weakening of economic
conditions that could adversely affect the level of demand for our products; pricing pressures
generally, including cost-containment measures that could adversely affect the price of or demand
for our products; changes in foreign exchange markets; legislative and regulatory actions;
unanticipated issues arising in connection with clinical studies and otherwise that affect U.S.
Food and Drug Administration approval of new products; changes in reimbursement levels from
third-party payors; a significant increase in product liability claims; the ultimate total cost
with respect to the Rejuvenate and ABG II matter; the impact of investigative and legal
proceedings and compliance risks; resolution of tax audits; the impact of the federal legislation
to reform the United States healthcare system and the 2.3 percent medical device excise tax;
changes in financial markets; changes in the competitive environment; our ability to integrate
acquisitions, including the acquisition of Trauson Holdings Company Limited; and our ability to
realize anticipated cost savings as a result of workforce reductions and other restructuring
activities. Additional information concerning these and other factors are contained in our filings
with the U.S. Securities and Exchange Commission, including our Annual Report on Form 10-K and
Quarterly Reports on Form 10-Q.

Stryker is one of the world's leading medical technology companies and is dedicated to helping
healthcare professionals perform their jobs more efficiently while enhancing patient care. The
Company offers a diverse array of innovative medical technologies, including reconstructive,
medical and surgical, and neurotechnology and spine products to help people lead more active and
more satisfying lives. 

Contacts

For media inquiries please contact:
Yin Becker, Stryker Corporation, 201-831-5000 or yin.becker@stryker.com

For investor inquiries please contact:
Katherine A. Owen, Stryker Corporation, 269-385-2600 or katherine.owen@stryker.com


---------------------------------------------------------------------------------------------------

This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the
information contained therein.

Source: Stryker Corporation via Thomson Reuters ONE


HUG#1686903

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.